WO2003094965A3 - Modulation of neural stem cells with s1p or lpa receptor agonists - Google Patents

Modulation of neural stem cells with s1p or lpa receptor agonists Download PDF

Info

Publication number
WO2003094965A3
WO2003094965A3 PCT/IB2003/002370 IB0302370W WO03094965A3 WO 2003094965 A3 WO2003094965 A3 WO 2003094965A3 IB 0302370 W IB0302370 W IB 0302370W WO 03094965 A3 WO03094965 A3 WO 03094965A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulation
stem cells
receptor agonists
neural stem
lpa receptor
Prior art date
Application number
PCT/IB2003/002370
Other languages
French (fr)
Other versions
WO2003094965A2 (en
WO2003094965A8 (en
Inventor
Per Lindquist
Alex Mercer
Harriet Ronnholm
Lilian Wikstrom
Original Assignee
Neuronova Ab
Per Lindquist
Alex Mercer
Harriet Ronnholm
Lilian Wikstrom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuronova Ab, Per Lindquist, Alex Mercer, Harriet Ronnholm, Lilian Wikstrom filed Critical Neuronova Ab
Priority to AU2003233119A priority Critical patent/AU2003233119A1/en
Publication of WO2003094965A2 publication Critical patent/WO2003094965A2/en
Publication of WO2003094965A3 publication Critical patent/WO2003094965A3/en
Publication of WO2003094965A8 publication Critical patent/WO2003094965A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

The invention relates generally to methods of influencing central nervous system cells to produce progeny useful in the treatment of CNS disorders. More specifically, the invention includes methods of exposing a patient suffering from such a disorder to a reagent that modulates the proliferation, migration, differentiation and survival of central nervous system cells via S1P or LPA signaling. These methods are useful for reducing at least one symptom of the disorder.
PCT/IB2003/002370 2002-05-08 2003-05-08 Modulation of neural stem cells with s1p or lpa receptor agonists WO2003094965A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003233119A AU2003233119A1 (en) 2002-05-08 2003-05-08 Modulation of neural stem cells with s1p or lpa receptor agonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37911402P 2002-05-08 2002-05-08
US60/379,114 2002-05-08
US39315902P 2002-07-02 2002-07-02
US60/393,159 2002-07-02

Publications (3)

Publication Number Publication Date
WO2003094965A2 WO2003094965A2 (en) 2003-11-20
WO2003094965A3 true WO2003094965A3 (en) 2004-07-22
WO2003094965A8 WO2003094965A8 (en) 2004-08-26

Family

ID=29423656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/002370 WO2003094965A2 (en) 2002-05-08 2003-05-08 Modulation of neural stem cells with s1p or lpa receptor agonists

Country Status (3)

Country Link
US (3) US20040014662A1 (en)
AU (1) AU2003233119A1 (en)
WO (1) WO2003094965A2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014662A1 (en) * 2002-05-08 2004-01-22 Per Lindquist Modulation of neural stem cells and neural progenitor cells
AU2003229140B2 (en) * 2002-06-07 2010-05-27 Es Cell International Pte Ltd Methods of regulating differentiation in stem cells
CA2488425A1 (en) * 2002-06-07 2003-12-18 Es Cell International Pte Ltd Methods of regulating differentiation in stem cells
US20040241839A1 (en) * 2003-04-11 2004-12-02 Svetlov Stanislav I. Culturing neural stem cells
US8491883B2 (en) * 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
AU2004252567B2 (en) * 2003-06-27 2011-10-06 Ethicon, Incorporated Repair and regeneration of ocular tissue using postpartum-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US8790637B2 (en) * 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
JP2005092331A (en) * 2003-09-12 2005-04-07 Hewlett-Packard Development Co Lp Information retrieval device and method
EP1663188B1 (en) * 2003-09-12 2016-08-10 Newron Sweden AB Treatment of disorders of the nervous system
US20070269412A1 (en) 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
GB0329498D0 (en) * 2003-12-19 2004-01-28 Novartis Ag Organic compounds
WO2006083394A2 (en) * 2004-12-21 2006-08-10 Ethicon, Inc. Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
US20060153815A1 (en) * 2004-12-21 2006-07-13 Agnieszka Seyda Tissue engineering devices for the repair and regeneration of tissue
US20060171930A1 (en) * 2004-12-21 2006-08-03 Agnieszka Seyda Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same
JP5425399B2 (en) 2004-12-23 2014-02-26 エシコン・インコーポレイテッド Treatment of Parkinson's disease and related disorders using postpartum-derived cells
CA2589041C (en) 2004-12-23 2019-08-20 Ethicon, Incorporated Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
WO2007016245A2 (en) * 2005-07-29 2007-02-08 Vivicells International, Llc Reprogramming of adult or neonic stem cells and methods of use
JP5289970B2 (en) * 2005-12-16 2013-09-11 エシコン・インコーポレイテッド Compositions and methods for inhibiting reverse immune responses in histocompatible incompatible transplants
WO2007073552A1 (en) * 2005-12-19 2007-06-28 Ethicon, Inc. In vitro expansion of postpartum derived cells in roller bottles
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US20070160588A1 (en) * 2005-12-28 2007-07-12 Ethicon, Incorporated Treatment Of Peripheral Vascular Disease Using Postpartum-Derived Cells
US8574567B2 (en) 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US20100291042A1 (en) 2007-05-03 2010-11-18 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
EP2203186B1 (en) * 2007-10-05 2014-09-24 DePuy Synthes Products, LLC Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
US8236538B2 (en) 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
WO2010068775A2 (en) 2008-12-11 2010-06-17 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
CA2747794C (en) 2008-12-19 2018-10-30 Advanced Technologies And Regenerative Medicine, Llc Treatment of lung and pulmonary diseases and disorders
EP2379087B1 (en) * 2008-12-19 2014-08-20 DePuy Synthes Products, LLC Umbilical cord tissue derived cells for treating neuropathic pain and spasticity
EP2379089B1 (en) * 2008-12-19 2019-04-17 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue following injury
US10179900B2 (en) * 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
US20100209399A1 (en) * 2009-02-13 2010-08-19 Celavie Biosciences, Llc Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects
BRPI1013409A2 (en) 2009-03-26 2018-01-16 Advanced Tech And Regenerative Medicine Llc human umbilical cord tissue cells as therapy for alzheimer's disease
SG176000A1 (en) * 2009-05-13 2011-12-29 Protein Delivery Solutions Llc Pharmaceutical system for trans-membrane delivery
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
WO2011005581A2 (en) * 2009-06-24 2011-01-13 Lpath, Inc. Methods of increasing neuronal differntiation using antibodies to lysophoshatidic acid
EP2462128B1 (en) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
EP2694496A1 (en) 2011-04-05 2014-02-12 Amira Pharmaceuticals, Inc. 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
EP2741756A4 (en) * 2011-08-09 2015-04-22 Lpath Inc Stem cell therapy using inhibitors of lysophosphatidic acid
US20140309291A1 (en) * 2011-11-11 2014-10-16 The Children's Hospital Of Philadelphia Compositions and Methods for Increasing Stress Resilience
JP6301263B2 (en) 2011-12-23 2018-03-28 デピュイ・シンセス・プロダクツ・インコーポレイテッド Detection of human umbilical cord tissue-derived cells
CA2913074C (en) 2013-05-30 2023-09-12 Graham H. Creasey Topical neurological stimulation
US11229789B2 (en) 2013-05-30 2022-01-25 Neurostim Oab, Inc. Neuro activator with controller
CN104367424A (en) * 2014-12-11 2015-02-25 常熟市新冶机械制造有限公司 Electric wheelchair with emergency call function
US11077301B2 (en) 2015-02-21 2021-08-03 NeurostimOAB, Inc. Topical nerve stimulator and sensor for bladder control
WO2019094365A1 (en) 2017-11-07 2019-05-16 Neurostim Oab, Inc. Non-invasive nerve activator with adaptive circuit
CA3144957A1 (en) 2019-06-26 2020-12-30 Neurostim Technologies Llc Non-invasive nerve activator with adaptive circuit
CA3152451A1 (en) 2019-12-16 2021-06-24 Michael Bernard Druke Non-invasive nerve activator with boosted charge delivery

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712262A (en) * 1996-11-21 1998-01-27 Spiegel; Sarah Use of sphingosine-1-phosphate to suppress programmed cell death
WO1999019513A2 (en) * 1997-10-10 1999-04-22 Lxr Biotechnology, Inc. Methods for detecting compounds which modulate the activity of an lpa receptor
WO2000009139A2 (en) * 1998-08-10 2000-02-24 The Regents Of The University Of California Methods for promoting survival of myelin producing cells
US6380177B1 (en) * 1999-06-25 2002-04-30 Atairgin Technologies, Inc. LPA analogs as agonists of the Edg2 LPA receptor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692147A (en) * 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5254380A (en) * 1985-11-22 1993-10-19 University Of Dayton Dry powder mixes comprising phase change materials
US5011678A (en) 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
US5011648A (en) * 1989-02-14 1991-04-30 Van Dorn Company System, method and apparatus for hot fill PET container
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5604229A (en) 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
US5670477A (en) * 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
HU224814B1 (en) 1995-12-28 2006-02-28 Mitsubishi Pharma Corp Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
US5711316A (en) * 1996-04-30 1998-01-27 Medtronic, Inc. Method of treating movement disorders by brain infusion
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH11209277A (en) 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd Pharmaceutical composition
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
JPH1180026A (en) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd New immunosuppressant, its use and its identification
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
WO2002042413A2 (en) * 2000-11-01 2002-05-30 Neuronova Ab Methods and compositions involved in groucho-mediated differentiation
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US20030165485A1 (en) * 2001-11-09 2003-09-04 Goran Bertilsson Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells
US20040038888A1 (en) * 2002-05-03 2004-02-26 Alex Mercer Functional role and potential therapeutic use of PACAP, VIP and Maxadilan in relation to adult neural stem or progenitor cells
US20040014662A1 (en) * 2002-05-08 2004-01-22 Per Lindquist Modulation of neural stem cells and neural progenitor cells
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
JP4509028B2 (en) 2002-09-24 2010-07-21 ノバルティス アーゲー Organic compounds
JP2007523858A (en) 2003-06-24 2007-08-23 ユニバーシティ オブ コネチカット Methods for inhibiting vascular permeability and apoptosis
EP1663188B1 (en) * 2003-09-12 2016-08-10 Newron Sweden AB Treatment of disorders of the nervous system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712262A (en) * 1996-11-21 1998-01-27 Spiegel; Sarah Use of sphingosine-1-phosphate to suppress programmed cell death
WO1999019513A2 (en) * 1997-10-10 1999-04-22 Lxr Biotechnology, Inc. Methods for detecting compounds which modulate the activity of an lpa receptor
WO2000009139A2 (en) * 1998-08-10 2000-02-24 The Regents Of The University Of California Methods for promoting survival of myelin producing cells
US6380177B1 (en) * 1999-06-25 2002-04-30 Atairgin Technologies, Inc. LPA analogs as agonists of the Edg2 LPA receptor

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AKIRA YOSHIDA ET AL: "Activation of Gi1 by Lysophosphatidic Acid Receptor without Ligand in the Baculovirus Expression System", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 259, 1999, pages 78 - 84, XP002260720, Retrieved from the Internet <URL:www.idealibrary.com> [retrieved on 20031106] *
AKIRA YOSHIDA ET AL: "Neurobiology of the Edg2 Lysophosphatidic Acid Receptor", JPN. J. PHARMACOL., vol. 87, 2001, pages 104 - 109, XP002260721 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2001, HARADA J ET AL: "Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells", XP002260727, Database accession no. PREV200100498277 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2001, NAM J S ET AL: "Survival of hippocampal neuroprogenitor cells by lysophosphatidic acid involves activation of cyclic AMP-response element binding protein", XP002260728, Database accession no. PREV200100549552 *
FIONA DOETSCH ET AL: "Cellular Composition and Three-Dimensional Organization of the Subventricular Germinal Zone in the Adult Mammalian Brain", THE JOURNAL OF NEUROSCIENCE, vol. 17, no. 13, 1 July 1997 (1997-07-01), pages 5046 - 5061, XP002260723, ISSN: 0270-6474 *
H. GEORG KUHN ET AL: "Epidermal Growth Factor and Fibroblast Growth Factor-2 Have Different Effects on Neural Progenitors in the Adult Rat Brain", THE JOURNAL OF NEUROSCIENCE, vol. 17, no. 15, 1 August 1997 (1997-08-01), pages 5820 - 5829, XP002260724, ISSN: 0270-6474 *
JEROLD CHUN ET AL: "International Union of Pharmacology. XXXIV. Lysophospholipid Receptor Nomenclature", PHARMACOL REV, vol. 54, no. 2, 2002, pages 265 - 269, XP002260722, ISSN: 0031-6997 *
NOBUYUKI FUKUSHIMA ET AL: "Neurobiology of Lysophosphatidic Acid Signaling", THE NEUROSCIENTIST, vol. 8, no. 6, 2002, pages 540 - 550, XP002260725 *
RACHELLE E. TOMAN ET AL: "Lysophospholipid Receptors in the Nervous System", NEUROCHEMICAL RESEARCH, vol. 27, no. 7/8, August 2002 (2002-08-01), pages 619 - 627, XP002260726, ISSN: 0364-3190 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, 2001, 31st Annual Meeting of the Society for Neuroscience;San Diego, California, USA; November 10-15, 2001, pages 1235, ISSN: 0190-5295 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, 2001, 31st Annual Meeting of the Society for Neuroscience;San Diego, California, USA; November 10-15, 2001, pages 933, ISSN: 0190-5295 *

Also Published As

Publication number Publication date
US7811822B2 (en) 2010-10-12
AU2003233119A8 (en) 2003-11-11
US20080213276A1 (en) 2008-09-04
US20040014662A1 (en) 2004-01-22
AU2003233119A1 (en) 2003-11-11
WO2003094965A2 (en) 2003-11-20
WO2003094965A8 (en) 2004-08-26
US20110189184A1 (en) 2011-08-04
US8318704B2 (en) 2012-11-27

Similar Documents

Publication Publication Date Title
WO2003094965A3 (en) Modulation of neural stem cells with s1p or lpa receptor agonists
WO2003092716A3 (en) Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
WO2003039575A3 (en) Use of reelin, gas6, and protein s in the treatment of neural disorders
HK1068501A1 (en) Pdgf-bb for the treatment of parkinson&#39;s disease
EP1474687A4 (en) Marks as modifiers of the p53 pathway and methods of use
WO2003074662A3 (en) SCDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
PT1687284E (en) P-38 kinase inhibitors
WO2004032851A3 (en) Screening and therapeutic methods relating to neurogenesis
IL177285A0 (en) Use of tweak modulators and inhibitors for the treatment of neurological conditions
ATE457309T1 (en) MODULATORS OF PERIPHERAL 5-HT RECEPTORS
EP1576180A4 (en) Ampk pathway components
EP1254260A4 (en) Methods for diagnosing and treating heart disease
WO2005061002A3 (en) Composition and methods for modulating cns activity
WO2002083182A3 (en) The effect of receptor protein tyrosine phosphatase sigma (rptp-$g(s)) on neural axon regeneration and synapse modification
AU2003211040A8 (en) The eaat2 promoter and uses thereof
MXPA05013196A (en) Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor.
ATE494551T1 (en) C20ORF23 AS A MODIFIER OF THE IGFR PATHWAY AND METHOD OF USE
WO2004036181A3 (en) Method of treating neurological diseases and disorders
WO2004015072A3 (en) Mrbs as modifiers of the rb pathway and methods of use
WO2003023048A3 (en) METHODS FOR DIAGNOSING AND TREATING DISEASES AND CONDITIONS ASSOCIATED WITH PROTEIN KINASE C$g(l)
WO2004048541A3 (en) Cct6s as modifiers of the rb pathway and methods of use
WO2004104168A3 (en) Mrbs as modifiers of the rb pathway and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP